Innocrin Pharmaceuticals announced the completion of a $28 million Series D financing round.
The financing was led by Eshelman Ventures and Fred Eshelman, PharmD., Founder of Eshelman Ventures, has joined Innocrin’s board of directors.
The company’s current investors: Novartis Venture Fund, Lilly Ventures, Hatteras Venture Partners, Intersouth Partners, and A&B Equity Holdings all participated in the fully subscribed round.
|Searching for more deal information? Current Partnering offers the following options:
Innocrin plans to use the proceeds to accelerate parallel Phase 2 CRPC program studies that are being led by the Memorial Sloan Kettering Cancer Center (MSK) and the NCI.
The company will also initiate an MSK-led Phase 1 / 2 study in women who have resistant breast cancer that either expresses the estrogen receptor (ER+ subtype) or does not express any of the accepted treatment biomarkers (triple-negative breast cancer or TNBC).
For further deal information visit Current Agreements (subscription required)
Scorecard: Top partnering deals by value in 2015
View: Top biotech companies